key: cord-0761617-gg4i51ko
authors: Gabitzsch, Elizabeth; Safrit, Jeffrey T.; Verma, Mohit; Rice, Adrian; Sieling, Peter; Zakin, Lise; Shin, Annie; Morimoto, Brett; Adisetiyo, Helty; Wong, Raymond; Bezawada, Ashish; Dinkins, Kyle; Balint, Joseph; Peykov, Victor; Garban, Hermes; Liu, Philip; Bone, Pete; Bacon, Andrew; Drew, Jeff; Sanford, Daniel C.; Spilman, Patricia; Sender, Lennie; Rabizadeh, Shahrooz; Niazi, Kayvan; Soon-Shiong, Patrick
title: Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
date: 2021-03-26
journal: bioRxiv
DOI: 10.1101/2020.12.08.416297
sha: 96fcfba1c38a5edb2fadc168a67b7d1c099061de
doc_id: 761617
cord_uid: gg4i51ko

We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified SARS-CoV-2 spike (S-Fusion) protein and the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) with the potential to increase MHC class I/II responses. The adenovirus serotype 5 platform used, hAd5 [E1-, E2b-, E3-], previously demonstrated to be effective in the presence of Ad immunity, can be delivered in an oral formulation that overcomes cold-chain limitations. The hAd5 S-Fusion + N-ETSD vaccine was evaluated in rhesus macaques showing that a subcutaneous prime followed by oral boosts elicited both humoral and Th1 dominant T-cell responses to both S and N that protected the upper and lower respiratory tracts from high titer (1 x 106 TCID50) SARS-CoV-2 challenge. Notably, viral replication was inhibited within 24 hours of challenge in both lung and nasal passages, becoming undetectable within 7 days post-challenge. ONE SENTENCE SUMMARY hAd5 spike + nucleocapsid SC prime/oral boost vaccine elicits humoral and T-cell responses and protects rhesus macaques from SARS-CoV-2 challenge.

To address the ongoing COVID-19 pandemic (1, 2), particularly in the face of viral evolution 48 and evidence of viral variant resistance to antibodies and convalescent plasma (3-6), we have 49 developed a vaccine anticipated to protect individuals from SARS-CoV-2 that has the potential to 50 not only elicit robust humoral responses but also activate T cells. The dual-antigen hAd5 S-Fusion 51 + N-ETSD vaccine ( Supplementary Fig. 1) CoV-2 convalescent individuals with the dual-antigen vaccine, incubated the S-Fusion and N-85 ETSD-expressing MoDCs with T cells from those same individuals, and saw that the vaccine 86

As shown in Figure 1 , all SC-Oral-Oral vaccinated NHP produced anti-S IgG that increased 140 after both the Day 14 and Day 28 oral boosts ( Fig. 1A and B) . Sera from 4 of 5 SC-Oral-Oral NHP, 141 taken at baseline and every week starting at Day 14 and up to Day 42, demonstrated inhibition in 142 the neutralization assay (Fig. 1C ) that assesses the inhibition of binding of S RBD to recombinant 143 angiotensin-converting enzyme 2 (ACE2) and is reported to correlate with the ability of sera to 144 neutralize the SARS-CoV-2 virus (40). 145

Anti-S IgG production was similar for SC-SC-Oral (where the first boost was SC) hAd5 S-146 Fusion + N-ETSD vaccinated NHP ( Fig. 1D 

CoV-2 challenge 159 RT-qPCR analysis of genomic RNA (gRNA) was performed on nasal swab and 160 bronchoalveolar lavage (BAL) samples to determine the amount of virus present. SC-Oral-Oral 161 vaccination of NHP reduced SARS-CoV-2 gRNA in the nasal swab samples as compared to 162 placebo control NHP from Day 57, the first day after challenge ( Fig. 2A In the group receiving an SC and oral boost (SC-SC-Oral), SARS-CoV-2 gRNA in nasal swab 171 samples was also reduced similarly to that seen in SC-Oral-Oral vaccinated primates, with viral 172 gRNA decreasing to levels that were very low or below the LOD in all vaccinated animals by Day 173 63 (Fig. 2E and F; Supplementary For sera collected in the post-challenge period, a microneutralization assay (see Methods) was 225 used to assess SARS-CoV-2 neutralization capability as reflected by the 'MN50', that is, the serum 226 dilution that correlates to a 50% reduction in viral infectivity as compared to a no-serum control. 227 A rapid increase in neutralization capability of sera for NHP receiving only oral boosts was seen 228 over the two weeks following challenge ( Our thermally-stable oral hAd5 S-Fusion + N-ETSD vaccine, due its expression of S and N, 294 also has the potential to act as a 'universal' boost to other previously administered vaccines that 295 deliver only S antigens. This use would also be facilitated by cold-chain independence and 296 warrants further exploration. 297

The hAd5 S-Fusion + N-ETSD vaccine delivered as an SC prime and boost is in Phase 1 298 clinical trials and the thermally-stable oral vaccine has entered Phase 1 trials as both a prime and 299 boost, and as a boost to an SC prime. 300 301 ACKNOWLEDGEMENTS 302

We would like to thank the following members of the Battelle group for their contributions 303

in the execution of this study; Chris Cirimotich, Katie Albanese, Phyllis Herr-Calomeni, Bradley 304

Brown, Sara Pfeifer, Carrie Fetzek, Ashley Hay, Andy Puttmann, Amy Allen, and Kevin Coty. 305

We thank Phil Yang of ImmunityBio for his ongoing coordination of project reports for this study. 306

We would also like to thank the DHHS, NIH/NIAID and ASPR/BARDA for funding the study. 307 The hAd5 S-Fusion + N-ETSD vaccine 455

To generate the hAd5 S-Fusion + N-ETSD vaccine we utilized the hAd5 [E1-, E2b-, E3-] 456 platform (Fig. S1A) into which a wildtype spike (S) (Fig. S1B ) sequence [accession number 457 YP009724390] modified with a proprietary linker peptide sequence was cloned and as well as 458 wildtype nucleocapsid (N) (Fig, S1B) ELISpot assay for assessment of cytokine secretion by T cells 505

ELISpot assays were used to detect cytokines secreted by splenocytes from inoculated mice. 506

Fresh splenocytes were used on the same day, as were cryopreserved splenocytes containing 507 lymphocytes. The cells (2-4 x 10 5 cells per well of a 96-well plate) were added to the ELISpot 508 plate containing an immobilized primary containing an immobilized primary antibody to either 509 IFN-g (BD catalogue # 512525) or IL-4 (BD catalogue # 511819), and were pulsed with 2 µg/ml 510 of SARS-CoV-2 S or N peptide pools (JPT Peptide Technologies catalogue # PM-WCPV-S-1 and 511

PM-WCPV-NCAP-1 respectively). Negative and positive controls were cells cultured with media 512 alone or Concanavalin A (ConA, 0.46 µg/ml), respectively. After aspiration and washing to 513 remove cells and media, cytokine secretion was detected by biotinylated antibodies to either IFN-514 g (BD catalogue # 551818) or IL-4 (BD catalogue # 551804), followed by labeling with a 515 secondary streptavidin/horseradish peroxidase conjugate (BD catalogue # 557630). Spot 516 development was completed using a peroxidase substrate kit (Vector Labs catalogue # SK-4200). 517

The number of spots per well (2-4 x 10 5 PBMCs) was counted using an ELISpot plate reader. 518

Numbers for graphing were adjusted to spot-forming cells per 10 6 PBMCs. 519 520

ELISA for detection of antibodies in the mouse study 521

For antibody detection in sera from inoculated mice, ELISAs specific for spike and 522

nucleocapsid antibodies, as well as for A standard curve of IgG was generated and absorbance values were converted into mass 547 equivalents for both anti-S and anti-N antibodies. Using these values, we were able to calculate 548 that hAd5 S-Fusion + N-ETSD vaccination generated a geometric mean value of 5.8 µg S-specific 549

IgG and 42 µg N-specific IgG per milliliter of serum. 550 551

The analysis of antibodies and subtypes, and ELISpot for IFN-g and IL-4 secretion ratios are shown 552

in Supplementary Figure S3 . 553 554

The NHP study 555 556

The Welfare Assurance approved facility. The study protocol was approved by the Institutional Animal 562

Care and Use Committee (ACUC). All aspects of the animal study protocol were designed to 563 minimize stress in the animals. 564 565

Dosing and sample collection 566 A total of 12 naïve rhesus macaques weighing >/= 2.5 Kg and being >2.5 years of age were 567 used in the study. All rhesus macaques were tested and confirmed negative within 45 days of 568 receipt for Mycobacterium tuberculosis, simian immunodeficiency virus (SIV), simian T-569 lymphotropic virus-I (STLV-1), simian retroviruses 1 and 2 (SRV-1 and SRV-2) via PCR, 570

Macacine herpesvirus I (Herpes B virus), and Trypanosoma cruzi (ELISA and PCR). 571

We compared two SC injections administered in the center of the back just caudal to the 572 scapular region of 1 x 10 11 vaccine particles (VP) of hAd5 S-Fusion + N-ETSD on Days 0 and 14 573 followed by an oral capsule 1x 10 10 infectious units (IU) of hAd5 S-Fusion + N-ETSD delivered 574 via a feeding tube after a minimum of 4 hours of fasting on Day 28 (SC-SC-Oral, Group 1) to one 575 prime SC injection and two oral boost doses with the same dosages and timing (SC-Oral-Oral, 576

Group 2), as shown in Supplementary Figure S4 . 577 Vaccination Group 1 (SC-SC-Oral comprised 3 male and 2 female, Group 2 (SC-Oral-Oral) 578 2 male and 3 female, and Group 3 (placebo) 1 male and 1 female randomized NHP. 579

On Day 42, NHPs were transferred to a BSL-3 facility and on Day 56 they were challenged 580 via the intratracheal (0.5 mL) and intranasal (0.25 mL per nares) routes with a total dose of 581 approximately 1 x10 6 TCID50 SARS- Supplementary Figure S5 , hematology in Table S1 and clinical chemistry in Table S2 . 604 605

Statistical analysis 606

For comparison of animals in groups, One-Way ANOVA was used with an appropriate post-607 hoc analysis (for example, Tukey's or Dunnett's) for specific comparisons. For head-to-head 608 analyses, a two-tailed unpaired Student's T-test was used. For all statistical analyses, *p <= 0.05, 609 **p < 0.01, ***p<0.001, and ****p<0.0001. All statistical analysis was performed using 610

GraphPad Prism 9 software. 611 612 Figure S5 . NHP body weights over the course of the study. Body weights are shown in Kg; note 748 y-axis range is 4-6 Kg. 749 750

Hematology 751

Hematological parameters evaluated in Group 1 and 2 hAd5 S-Fusion + N-ETSD and Group 752 3 placebo control animals are presented in Table S1 . Only hemoglobin was consistently slightly 753 lower in Group 2 NHP as compared to Group 3 placebo for all post-vaccination time points. 754 755 Table S1 . Viral load was also determined in BAL samples. Gene copies per mL for individual NHP are 789

shown in Table S4.  790  791  Table S4 . Gene copies per mL for gRNA as determined by RT qPCR in BAL samples for all groups. 792

Values below the level of detection (LOD) of 54 gene copies per mL (GC/mL) are highlighted in 793

yellow. For calculation of the geometric mean, half the LOD values (27 GC/mL) was used. 794

Viral sgRNA in nasal swab samples 797 798

Gene copies per mL of subgenomic RNA (sgRNA) for individual NHP are shown in Table  799 S5. 800 801 Table S5 . Data 

Surface expression of spike receptor binding domain ( RBDS) in hAd5 S-wildtype (W), hAd5 S-707 Fusion

Cell surface expression of S RBD was enhanced with hAd5 S-Fusion compared to hAd5 S-WT, 710 and the dual-antigen hAd5 S-Fusion + N-ETSD construct further enhanced cell surface expression 711 in transduced HEK-293T cells, as shown in Fig

Cell surface 715 expression of S RBD after transduction of human embryonic kidney (HEK)-293T cells as detected 716 by flow cytometry (normalized to mode, NM) using an anti-RBD antibody with (A) hAd5 S-717 wildtype (S-WT), (B) hAd5 S-Fusion, (C) hAd5 S-Fusion + N-ETSD, or (D) hAd5 Null control 718 reveals increased surface expression of S RBD by S-Fusion that is further enhanced in S-Fusion

hAd5 S-Fusion + N-ETSD vaccination of CD-1 mice elicits Th1 helper cell dominant antibody and 722 T-cell responses 723

CD-1 mice vaccinated with the hAd5 S-Fusion + N-ETSD construct produced significantly higher 725 anti-S IgG than mice receiving hAd5 S-WT (Fig. S3A)

Anti-S IgG and Th1 dominance in hAd5 S-Fusion + N-ETSD vaccinated mice

Statistical analysis performed 731 using One-way ANOVA and Tukey's post-hoc comparison of groups. (B) In mice, both anti-S and 732 anti-nucleocapsid (N) antibody responses were Th1 dominant, as were (C) T-cell responses

No clinical signs were noted during the twice daily observations for clinical signs of toxicity 741 due to vaccination and no animals died during the two weeks after one subcutaneous immunization 742 of 1x 10 11 VP or a week after an oral booster of 1x10 10 IU of hAd5-S-Fusion+N-ETSD. No gross 743 pathological effect or adverse events were observed and there were no notable changes in body 744 weight

Group 1 NHP on five time points and at two time 765 points for Group 2 (Table S2), but it was lower on Day 0 baseline, indicating this was not vaccine-766 related. Data in Table S3

Clinical chemistry for hAd5 S-Fusion + N-ETSD vaccinated Group 1 and Group 2 NHP 769 as compared to placebo Group 3. ND -not significantly different from placebo

Viral load was determined in nasal swab samples by RT qPCR of genomic RNA. The data for 776 individual NHP at time point post-challenge are shown in Table S3

Gene copies per mL for gRNA as determined by RT qPCR in nasal passages for all 779 groups. Values below the level of detection (LOD) of 54 gene copies per mL (GC/mL) are 780 highlighted in yellow. For calculation of the geometric mean

IgG against recombinant spike protein in NHP sera or plasma was determined using an 614Enzyme-Linked ImmunoSorbent Assay (ELISA) wherein 96 well EIA/RIA plates (ThermoFisher,  615 Cat# 07-200-642) were coated with 50 µL/well by a 1 µg/mL solution of purified recombinant 616 SARS-CoV-2-derived Spike protein (S-Fusion; ImmunityBio, Inc.) suspended in coating buffer 617 (0.05 M carbonate-bicarbonate, pH 9.6) and incubated overnight at 4°C. Plates were washed three 618 times with 150 µL of TPBS solution (PBS + 0.05%Tween 20) then 100 µL/well of blocking 619 solution (2% non-fat milk in TPBS) was added and incubated for 1 hour at room temperature (RT). 620Plasma and serum samples were heat-inactivated at 56°C for 1 hour before use and 1:50 dilutions 621were prepared in 1% non-fat milk in TPBS. Plates were washed as described above and 50 µL/well 622 of each dilution was added to the plate and incubated at RT for 1 hour. binding domain (RBD) to its human host receptor (in the assay, recombinant) angiotensin 637 converting enzyme 2 (ACE2), with inhibition above 20% being correlated with a level of anti-S 638 antibody that is predicted to be neutralizing. All sera samples were diluted 1:30. 639 640ELISpot for assessment of cytokine secretion 641ELISpot assays were used to detect cytokines secreted by fresh peripheral blood mononuclear 642 cells (PBMCs) isolated from the blood of NHP study animals. PBMCs were isolated from whole 643 blood by standard density gradient centrifugation and frozen in liquid nitrogen until use. PBMCs 644were thawed and re-suspended in RPMI 10% human AB serum, then pulsed with 2 µg/ml of 645 SARS-CoV-2 S or N peptide pools (JPT Peptide Technologies catalogue # PM-WCPV-S and PM-646 WCPV-NCAP-1 respectively). Negative and positive controls were cells cultured with media 647 alone or phorbol myristate acetate (PMA, 50 ng/ml) and ionomycin (1 µg/ml), respectively. For 648 IFN-γ assessment, PBMCs were cultured (17 hours at 37°C) in a microtiter plate (Millipore 649 catalogue # MAIPS4510) containing an immobilized primary antibody to capture NHP-specific 650 IFN-g (MabTech catalogue # 3421M-3-1000). IFN-g was detected by a secondary antibody to 651 human IFN-g conjugated to biotin (MabTech catalogue # 3420-6-250). A streptavidin/horseradish 652 peroxidase conjugate (Thermo Fisher catalogue # 21126) was used detect the biotin-conjugated 653 secondary antibody. IFN-γ spot development was completed using a peroxidase substrate kit 654 (Vector Labs catalogue # SK-4200). The number of spots per well (3.5 x 10 5 PBMCs) was counted 655using an ELISpot plate reader. IL-4 was assessed using a commercial ELISpot kit (MabTech 656 catalogue # 3410-APW-2) using the manufacturer's instructions. Numbers for graphing were 657 adjusted to spot-forming cells per 10 6 PBMCs. 658

RT-qPCR assays were performed to quantify total SARS-CoV-2 RNA copies including 660 genomic RNA using the nucleocapsid protein gene as a target or subgenomic RNA copies that are 661 replication intermediates of the virus using the envelope protein (E) gene as a target. These assays 662were performed to quantify viral loads following SARS-CoV-2 challenge. RNA was isolated from 663 swabs and bronchioalveolar lavage fluid using the Indispin QIAcube HT Pathogen Kit (Indical 664Bioscience, Germany) on the QIAcube HT instrument (Qiagen, Germany). The isolated RNA was 665 then evaluated in RT-qPCR using the TaqMan Gene copies per mL of subgenomic RNA (sgRNA) for individual NHP are shown in Table  815 S5. 816 817 Table S6 . Data